Results 71 to 80 of about 4,877,471 (249)

A case of mistaken identity: When lupus masquerades as primary myelofibrosis

SAGE Open Medical Case Reports, 2013
Introduction: Autoimmune myelofibrosis is an uncommon hematologic disease characterized by anemia, bone marrow myelofibrosis, and an autoimmune feature. Myelofibrosis is often associated with other conditions, including infections, nutritional/endocrine ...
Edy Hasrouni, Heesun J Rogers, Ali Tabarroki, Valeria Visconte, Fabiola Traina, Manuel Afable, Mikkael A Sekeres, Jaroslaw P Maciejewski, Ramon V Tiu   +8 more
doaj   +1 more source

The Calreticulin gene and myeloproliferative neoplasms [PDF]

, 2016
The Philadelphia negative myeloproliferative neoplasms include polycythaemia vera (PV), essential thrombocytopenia (ET) and primary myelofibrosis (PMF).
Clinton, Aoibhinn, McMullin, Mary Frances   +1 more
core   +1 more source

Revised cytogenetic risk stratification in primary myelofibrosis: analysis based on 1002 informative patients

Leukemia, 2018
Current cytogenetic risk stratification in primary myelofibrosis (PMF) is two-tiered: ‘favorable’ and ‘unfavorable’. Recent studies have suggested prognostic heterogeneity within the unfavorable risk category.
A. Tefferi, M. Nicolosi, M. Mudireddy, T. Lasho, N. Gangat, K. Begna, C. Hanson, R. Ketterling, A. Pardanani   +8 more
semanticscholar   +1 more source

Drug Repositioning of Pegbing® for Essential Thrombocythemia: Insights from PK/PD Modeling and Extrapolation

Clinical Pharmacology &Therapeutics, EarlyView.
Pegbing® (peginterferon alfa‐2b), a pegylated interferon‐alpha, is approved for the treatment of chronic hepatitis B (CHB) and C. One of its adverse effects is platelet (PLT) suppression. It is currently being repurposed for the treatment of essential thrombocythemia (ET), a rare myeloproliferative disorder characterized by abnormally elevated PLT ...
Weizhe Jian, Yalin Yin, Rong Chen, Junsheng Xue, Jianbo Gu, Zhengfang Du, Ruoyi He, Tianyan Zhou   +7 more
wiley   +1 more source

The diagnosis and management of the haematologic manifestations of lupus [PDF]

, 2016
Haematological manifestations in systemic lupus erythematosus (SLE) are frequently observed. They are diverse and range from mild to severe.
Castro, SG, Isenberg, DA, Velo-García, A   +2 more
core   +1 more source

Leukemic transformation among 1306 patients with primary myelofibrosis: risk factors and development of a predictive model

Blood Cancer Journal, 2019
Among 1306 patients with primary myelofibrosis (PMF), we sought to identify risk factors that predicted leukemic transformation (LT) in the first 5 years of disease and also over the course of the disease.
Rangit R. Vallapureddy, M. Mudireddy, D. Penna, T. Lasho, C. Finke, C. Hanson, R. Ketterling, K. Begna, N. Gangat, A. Pardanani, A. Tefferi   +10 more
semanticscholar   +1 more source

Transition Metal‐Free Ortho‐Deuteration of Electron‐Deficient N‐Heteroarenes

European Journal of Organic Chemistry, EarlyView.
Herin, the metal‐free, selective deuteration of electron‐deficient N‐heteroaromatics is reported using O‐carbamate and carboxamide ortho‐directing groups (DGs), lithium 2,2,6,6‐tetramethylpiperidide as the base, and D2O as a green source of D+. The substrate scope includes 10 small molecule N‐heteroaromatic compounds and two pharmaceutically relevant ...
Žiga Oražem, Luka Jedlovčnik, Jernej Birk, Andrej Pevec, Ross D. Jansen‐van Vuuren, Janez Košmrlj   +5 more
wiley   +1 more source

Clinical features and therapeutic outcome of 30 patients diagnosed with primary myelofibrosis at the national center of hematology

مجلة كلية الطب, 2015
Background: Primary myelofibrosis is characterized by clonal expansion of hematopoietic stem cell with a non-reactive clonal proliferation of fibroblasts and bone marrow fibrosis, which occurs at an extramedullary hematopoiesis.
Alaa F. Alwan
doaj   +1 more source

Mutant calreticulin knockin mice develop thrombocytosis and myelofibrosis without a stem cell self-renewal advantage. [PDF]

, 2018
Somatic mutations in the endoplasmic reticulum chaperone calreticulin (CALR) are detected in approximately 40% of patients with essential thrombocythemia (ET) and primary myelofibrosis (PMF).
Aungier, Juliet, Bennett, Cavan, Dovey, Oliver M, Ghevaert, Cedric, Gonzalez-Arias, Carlos, Green, Anthony R, Grinfeld, Jacob, Hamilton, Tina L, Kent, David G, Klampfl, Thorsten, Li, Juan, Loughran, Stephen, Park, Hyun Jung, Pask, Dean C, Prins, Daniel, Sneade, Rachel, Vassiliou, George S, Williams, Matthew   +17 more
core   +1 more source

Hepcidin is elevated in primary and secondary myelofibrosis and remains elevated in patients treated with ruxolitinib

British Journal of Haematology, 2022
a peptide a key regulator of iron in an hepcidin levels can restricted erythro-poiesis and anaemia. myeloproliferative neoplasm (MPN) in we in 99 patients 49 and (SMF) Twenty- four of these patients ruxolitinib a JAK1/2 inhibitor for treatment of MF.
A. Zhou, Tim Kong, Jared S. Fowles, Chun‐Ling Jung, Maggie J. Allen, Daniel A. C. Fisher, M. Fulbright, E. Nemeth, T. Ganz, S. Oh   +9 more
semanticscholar   +1 more source